Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure.
Sunny MalhotraLaura Hurtado-NavarroAgustín PappollaLuisa Maria VillarJordi RíoXavier MontalbanPablo PelegrinManuel Comabella LopezPublished in: Neurology(R) neuroimmunology & neuroinflammation (2023)
The differential effect of fingolimod on the formation of an inflammasome-triggered ASC oligomer in monocytes between responders and nonresponders could be used as a response biomarker after 6 months of fingolimod treatment and suggests that fingolimod may exert their beneficial effects by reducing inflammasome signaling in a subset of patients with MS.